Safety of pembrolizumab for the treatment of melanoma

Expert Opinion on Drug Safety

Volumn 14, Issue 6, 2015, Pages 957-964

  Martin Liberal, Juan ^a   Kordbacheh, Tiana ^a   Larkin, James ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Cytotoxic T lymphocyte associated protein 4; Immune checkpoint; Immunotherapy; Ipilimumab; Melanoma; Nivolumab; Pembrolizumab; Programmed death 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DACARBAZINE; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADRENAL INSUFFICIENCY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; AUTOIMMUNE HEPATITIS; COLITIS; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EARLY DIAGNOSIS; FATIGUE; HEADACHE; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; KIDNEY FAILURE; LIVER TOXICITY; MACULOPAPULAR RASH; MASTALGIA; MELANOMA; MYALGIA; NAUSEA; PANCREATITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SIDE EFFECT; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; SKIN NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; HUMANS; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS;

EID: 84929589845     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1021774     Document Type: Article

References (42)

1. Eggermont AM, Kroemer G, Zitvogel L. Immunotherapy and the concept of a clinical cure. Eur J Cancer 2013;49(14):2965-7
2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23 . Positive Phase III trial of ipilimumab in patients with advanced melanoma.
3. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364(26):2517-26 . Second positive Phase III trial of ipilimumab in advanced melanoma.
4. Available from: http://www.accessdata. fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.DrugDetails
5. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002213/human-med-001465.jsp&mid=WC0b01ac058001d124
6. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm412861.htm
7. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24(2):207-12
8. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369(2):134-44 .. Phase I trial of pembrolizumab which demonstrated its favourable safety profile.
9. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dosecomparison cohort of a Phase 1 trial. Lancet 2014;384(9948):1109-17 .. Results of a randomized dosecomparison cohort of the Phase I trial of pembrolizumab in patients with advanced melanoma refractory to ipilimumab.
10. Gangadhar TC, Vonderheide RH. Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol 2014;11(2):91-9
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74
12. Miska J, Bas E, Devarajan P, et al. Autoimmunity-mediated antitumor immunity: tumor as an immunoprivileged self. Eur J Immunol 2012;42(10):2584-96
13. Oble DA, Loewe R, Yu P, et al. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 2009;9:3
14. Merelli B, Massi D, Cattaneo L, et al. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol 2014;89(1):140-65
15. Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007;8(3):239-45
16. Kinter AL, Godbout EJ, McNally JP, et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008;181(10):6738-46
17. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192(7):1027-34
18. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001;2(3):261-8
19. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol 2008;26:677-704
20. Dong H, Strome SE, Salomao DR, et al. Tumor-Associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8(8):793-800
21. Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004;10(15):5094-100
22. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65(3):1089-96
23. Postow MA, Harding J, Wolchok JD. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J 2012;18(2):153-9
24. Hino R, Kabashima K, Kato Y, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010;116(7):1757-66
25. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-47
26. Patnaik A KS, Tolcher AW, et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. J Clin Oncol 2012;2012(Suppl 2512):A
27. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010;37(5):430-9
28. Shih K, Arkenau HT, Infante JR. Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014;74(17):1993-2013
29. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013;31(5):616-22
30. Available from: http://www.esmo.org/Oncology-News/Nivolumab-Receives-Manufacturing-And-Marketing-Approvalin-Japan-for-the-Treatment-of-Unresectable-Melanoma. 2014
31. Melero I, Grimaldi AM, Perez-Gracia JL, et al. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013;19(5):997-1008
32. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32(10):1020-30
33. Robert C, Long GV, Brady B, et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med 2015;372(4):320-30 .. Clinical trial which showed good efficacy and safety results of the anti-PD-1 drug nivolumab in untreated melanoma patients.
34. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369(2):122-33 .. Phase I trial which showed acceptable toxicity profile and encouraging preliminary efficacy results of the combination of nivolumab and ipilimumab in advanced melanoma.
35. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515(7528):558-62
36. Furness AJ, Vargas FA, Peggs KS, et al. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol 2014;35(7):290-8
37. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003;198(1):63-9
38. Guleria I, Gubbels Bupp M, Dada S, et al. Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol 2007;125(1):16-25
39. Kochupurakkal NM, Kruger AJ, Tripathi S, et al. Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes. PLoS One 2014;9(2):e89561
40. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366(26):2455-65 . Phase I trial of anti-PD-L1 antibody which showed favourable profile of side effects.
41. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30(21):2691-7
42. Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013;368(14):1365-6 . Short communication of unacceptable hepatotoxicity of the combination of vemurafenib and ipilimumab.